All News

Michele Belcher, president of the National Community Pharmacists Association, and pharmacist and pharmacy owner at Grants Pass Pharmacy, discusses ways of transforming the pharmacy profession’s current challenges into opportunities for positive change for the profession.

Encorafenib in combination With anti-EGFR monoclonal antibody improves overall survival.

Implementation, communication, and assessment are critical steps to ensure patient safety.

Olaparib (Lynparza) was found to significantly improve overall survival in patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

Michael Abrams, MPH, PhD, senior health researcher at Public Citizen’s Health Research Group, discusses actions needed to help manage the opioid epidemic in the country.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses some key developments in the field of gynecologic oncology that will be on the agenda at the SGO 2022 annual meeting.

Phase 3 trial results also indicate that Alzheimer disease clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeks.

Trial of empagliflozin (Jardiance) in adults with chronic kidney disease will end early based on a recommendation from the trial’s Independent Data Monitoring Committee based on clear positive efficacy.

Jeffrey B. Simon, JD, co-chair of the National Opioid Litigation Conference, discusses the historic settlement in a multi-district opioid lawsuit in Texas.

Explain to patients that research Is continually evolving and the need for booster shots does not mean the vaccinations do not work.

Patients treated with upadacitinib achieved clinical remission of ulcerative colitis more frequently through weeks 8 and 52 versus the placebo group.

Agency hopes green light for complex drug device combination improves competition and access more affordable medications.

Nucala is an IL-5 antagonist monoclonal antibody (immunoglobulin G1 kappa) for the add-on maintenance treatment of adult and pediatric patients with severe asthma and with an eosinophilic phenotype.

Zegerid is indicated for the treatment of frequent heartburn.

All patients present opportunities, but patients who might be considered more challenging due to their condition are often the cases where pharmacists might make the greatest difference

Patients may not admit or recognize when they have a brain injury, but pharmacists can be a valuable resource.

The medications may also help tackle the global problem of antibiotic resistance, investigators say.

Investigators call for routine monitoring of vaccination effectiveness as the pandemic continues to evolve.

Corium’s Adlarity system lowers the likelihood of adverse gastrointestinal (GI) events that are normally associated with the oral medication.

The KEYLYNK-010 trial was evaluating a combination of pembrolizumab (Keytruda) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer who progressed following chemotherapy and either abiraterone acetate (Zytiga) or enzalutamide (Xtandi).

This month's generic product news features lanreotide injections, glycopyrrolate oral solution, and vasopressin.

Pfizer Inc and BioNTech seek approval for an additional fourth booster dose of their COVID-19 vaccine for adults 65 years of age and older who received an initial booster of any of the authorized or approved COVID-19 vaccines.

Galcanezumab-gnlm (Emgality) is indicated in adults for the preventive treatment of migraine and treatment of episodic cluster headache.

Co Q-10 helps to support a healthy heart and cardiovascular system.

Pharmacy Times spoke with students at the Idaho State University College of Pharmacy and its partner program at the University of Alaska Anchorage College of Health.

The median survival time of patients was 12 months compared with 7 in the control group, the analysis demonstrates.

Analysis assessing data from the world’s largest twin registry also finds evidence that genetic factors for strong headaches may differ between men and women.

The research team used the National Cancer Institute’s Surveillance, Epidemiology, and End Results database, which provides nationwide information on cancer statistics.

Ramucirumab (Cyramza; Eli Lilly) is FDA-approved for 5 unique cancer indications.

The global impact of GBS causes approximately 150,000 deaths of babies each year.